Researchers demonstrate that a bacteria can be modified to act as ‚living medicine‘ in the lung. The treatment significantly reduced acute lung infections in mice and doubled their survival rate. It showed no signs of toxicity in the lungs and once the treatment had finished its course, it was cleared by the immune system in a period of four days. The treatment also cleared biofilms that accumulate on the surface of endotracheal tubes used by patients with ventilator-associated pneumonia, which is one of the leading causes of mortality in intensive care units. The study paves the way for researchers to repurpose the bacteria to treat other types of lung diseases such as cancer, asthma or pulmonary fibrosis.
Quelle: ScienceDaily | Asthma
Titelbild/Grafik by ScienceDaily News
Kommentare und FragenMöchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Asthma
- 'Living medicine' created to tackle drug-resistant lung infections
- Specific outdoor air pollutants linked to asthma attacks in urban children
- COVID-19 booster increases durability of antibody response, research shows
- Researchers find missing piece of the asthma puzzle
- Salton Sea dust triggers lung inflammation, research finds
- Persistent asthma linked to increased buildup of plaque in arteries leading to the brain
- The body's own cannabinoids widen the bronchial tubes
- Smartphones are reservoirs of allergens according to new research
- Lowest pollen counts occur between 4:00 a.m. and noon
- Insight into immune mechanisms of inflammatory disease